Description

Multiple Myeloma (MM) is the 2nd most common hematological disorder and is characterized by accumulation of neoplastic plasma cells in the bone marrow. Despite significant therapeutic advances, the majority of patients inevitably relapse due to an incomplete eradication of residual cancer cells. MM could be an ideal tumor for immunotherapy as cancer cells express a unique idiotype antigen on the cell surface, a feature that is shared with other B-cell neoplasms. The idiotype is exclusively present on the cancer cells and not on any normal cell, and is different in each patient. So the therapy must be personalized, made especially for this patient. To be cost- and time effective, the therapy should be made easily, with minimal
differences in the manufacturing process between each individual therapy. In the current project we aim to develop an individualized type of immune therapy, the so-called CAR-T cell therapy. In this therapy, the patient's immune cells are isolated from blood and modified in such a way that they specifically recognize the idiotype on the malignant plasma cells and kill them. We will develop a fast and reliable procedure to generate small elements, so-called nanobodies, that can specifically recognize the patient's idiotype. When these nanobodies are put on the surface of immune cells, we
predict that they will efficiently direct the immune cell to the malignant clonal B cell. As such we aim to target MM residual cells and prevent disease relapse.
AcronymFWOAL963
StatusActive
Effective start/end date1/01/2031/12/23

    Flemish discipline codes

  • Applied immunology
  • Cancer therapy

    Research areas

  • CAR-T cells, Multiple Myeloma, Nanobodies

ID: 49114743